Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal
Most Observers Still Want More Detailed Data From Urothelial Cancer Study
Seagen/Astellas announced Phase Ib/II trial data for the combination that could lead to an accelerated approval for the antibody-drug conjugate in first-line bladder cancer.
You may also be interested in...
Former Novartis executive and venture capitalist David Epstein will step in to lead Seagen after its founder resigned in a scandal and amid M&A speculation.
Merck & Co’s mega-blockbuster checkpoint inhibitor Keytruda hit new clinical highs and lows at ESMO as the major ramps up efforts to expand the drug’s label by exploring novel combinations and cancer settings.
Eric Rubin, who heads up early oncology clinical development at Merck Research Laboratories, tells Scrip that it became clear very early on that Keytruda was something special.